| Autor: |
Santonen, Tiina, Mahiout, Selma, Alvito, Paula, Apel, Petra, Bessems, Jos, Bil, Wieneke, Borges, Teresa, Bose-O'Reilly, Stephan, Buekers, Jurgen, Cañas Portilla, Ana Isabel, Calvo, Argelia Castaño, de Alba González, Mercedes, Domínguez-Morueco, Noelia, López, Marta Esteban, Falnoga, Ingrid, Gerofke, Antje, Caballero, María Del Carmen González, Horvat, Milena, Huuskonen, Pasi, Kadikis, Normunds, Kolossa-Gehring, Marike, Lange, Rosa, Louro, Henriqueta, Martins, Carla, Meslin, Matthieu, Niemann, Lars, Díaz, Susana Pedraza, Plichta, Veronika, Porras, Simo P, Rousselle, Christophe, Scholten, Bernice, Silva, Maria João, Šlejkovec, Zdenka, Tratnik, Janja Snoj, Joksić, Agnes Šömen, Tarazona, Jose V, Uhl, Maria, Van Nieuwenhuyse, An, Viegas, Susana, Vinggaard, Anne Marie, Woutersen, Marjolijn, Schoeters, Greet |
| Přispěvatelé: |
Centre for Toxicogenomics and Human Health (ToxOmics), NOVA Medical School|Faculdade de Ciências Médicas (NMS|FCM), Centro de Investigação em Saúde Pública (CISP/PHRC), Comprehensive Health Research Centre (CHRC) - Pólo ENSP, Escola Nacional de Saúde Pública (ENSP) |
| Jazyk: |
angličtina |
| Rok vydání: |
2023 |
| Předmět: |
|
| Popis: |
Funding: This project received funding from the European Union’s Horizon 2020 research and innovation programme under grant agreement No 733032 HBM4EU, and co-funding from the authors’ organisations. The results presented here are based on a huge body of work performed as part of Task 5.3 of the HBM4EU in 2017–2022. First and foremost, we would like to acknowledge all our Task 5.3 colleagues for their valuable contribution to the project work, including the individual RAs and EBoD calculations. In addition, we would like to thank all our other HBM4EU colleagues, the HBM4EU-aligned study data owners, and the other stakeholders who provided support for and feedback on our work during its course. One of the aims of the European Human Biomonitoring Initiative, HBM4EU, was to provide examples of and good practices for the effective use of human biomonitoring (HBM) data in human health risk assessment (RA). The need for such information is pressing, as previous research has indicated that regulatory risk assessors generally lack knowledge and experience of the use of HBM data in RA. By recognising this gap in expertise, as well as the added value of incorporating HBM data into RA, this paper aims to support the integration of HBM into regulatory RA. Based on the work of the HBM4EU, we provide examples of different approaches to including HBM in RA and in estimations of the environmental burden of disease (EBoD), the benefits and pitfalls involved, information on the important methodological aspects to consider, and recommendations on how to overcome obstacles. The examples are derived from RAs or EBoD estimations made under the HBM4EU for the following HBM4EU priority substances: acrylamide, o-toluidine of the aniline family, aprotic solvents, arsenic, bisphenols, cadmium, diisocyanates, flame retardants, hexavalent chromium [Cr(VI)], lead, mercury, mixture of per-/poly-fluorinated compounds, mixture of pesticides, mixture of phthalates, mycotoxins, polycyclic aromatic hydrocarbons (PAHs), and the UV-filter benzophenone-3. Although the RA and EBoD work presented here is not intended to have direct regulatory implications, the results can be useful for raising awareness of possibly needed policy actions, as newly generated HBM data from HBM4EU on the current exposure of the EU population has been used in many RAs and EBoD estimations. publishersversion published |
| Databáze: |
OpenAIRE |
| Externí odkaz: |
|
